These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25266372)

  • 21. Sofosbuvir for previously untreated chronic hepatitis C infection.
    Hsu CS
    N Engl J Med; 2013 Aug; 369(7):678. PubMed ID: 23944317
    [No Abstract]   [Full Text] [Related]  

  • 22. New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C.
    Mariño Z; van Bömmel F; Forns X; Berg T
    Gut; 2014 Feb; 63(2):207-15. PubMed ID: 24253934
    [No Abstract]   [Full Text] [Related]  

  • 23. Two Antiviral Drugs Approved For Adolescents With HCV.
    Aschenbrenner DS
    Am J Nurs; 2017 Aug; 117(8):22. PubMed ID: 28749879
    [No Abstract]   [Full Text] [Related]  

  • 24. Haemophilia-related outcome after liver transplantation and treatment with sofosbuvir/ribavirin in a HCV-HIV coinfected man with liver failure and hepatocellular carcinoma.
    Stemberger M; Seybold U; Eberle J; Denk G; Kolligs F; Kaspar M; Guba M; Pichler M; Spannagl M
    Haemophilia; 2015 Mar; 21(2):e131-e133. PubMed ID: 25622556
    [No Abstract]   [Full Text] [Related]  

  • 25. Sustained virological response with sofosbuvir and ledipasvir for hepatitis C virus genotype 5.
    Rivero-Juárez A; Rivero A
    Lancet Infect Dis; 2016 Apr; 16(4):392-3. PubMed ID: 26803445
    [No Abstract]   [Full Text] [Related]  

  • 26. Sofosbuvir for previously untreated chronic hepatitis C infection.
    Lawitz E; Mangia A; Wyles D; Rodriguez-Torres M; Hassanein T; Gordon SC; Schultz M; Davis MN; Kayali Z; Reddy KR; Jacobson IM; Kowdley KV; Nyberg L; Subramanian GM; Hyland RH; Arterburn S; Jiang D; McNally J; Brainard D; Symonds WT; McHutchison JG; Sheikh AM; Younossi Z; Gane EJ
    N Engl J Med; 2013 May; 368(20):1878-87. PubMed ID: 23607594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
    Jacobson IM; Gordon SC; Kowdley KV; Yoshida EM; Rodriguez-Torres M; Sulkowski MS; Shiffman ML; Lawitz E; Everson G; Bennett M; Schiff E; Al-Assi MT; Subramanian GM; An D; Lin M; McNally J; Brainard D; Symonds WT; McHutchison JG; Patel K; Feld J; Pianko S; Nelson DR; ;
    N Engl J Med; 2013 May; 368(20):1867-77. PubMed ID: 23607593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon free hepatitis C treatment regimens: the beginning of another era.
    Poordad F; Chee GM
    Curr Gastroenterol Rep; 2012 Feb; 14(1):74-7. PubMed ID: 22105465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapy for hepatitis C--the costs of success.
    Hoofnagle JH; Sherker AH
    N Engl J Med; 2014 Apr; 370(16):1552-3. PubMed ID: 24725236
    [No Abstract]   [Full Text] [Related]  

  • 30. Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.
    Gray E; O'Leary A; Bergin C; Cannon M; Courtney G; Crosbie O; De Gascun CF; Fanning LJ; Feeney E; Houlihan DD; Kelleher B; Lambert JS; Lee J; Mallon P; McConkey S; McCormick A; McKiernan S; McNally C; Murray F; Sheehan G; Stewart S; Walsh C; Norris S;
    Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):593-601. PubMed ID: 28276815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
    Zeuzem S; Dusheiko GM; Salupere R; Mangia A; Flisiak R; Hyland RH; Illeperuma A; Svarovskaia E; Brainard DM; Symonds WT; Subramanian GM; McHutchison JG; Weiland O; Reesink HW; Ferenci P; Hézode C; Esteban R;
    N Engl J Med; 2014 May; 370(21):1993-2001. PubMed ID: 24795201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Pearlman BL; Ehleben C; Perrys M
    Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.
    Serfaty L
    Liver Int; 2015 Jan; 35 Suppl 1():18-20. PubMed ID: 25529083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
    Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C genotype 3: a tough match for interferon-free regimens.
    Aghemo A; Colombo M
    Gastroenterology; 2014 Apr; 146(4):1125-7. PubMed ID: 24566101
    [No Abstract]   [Full Text] [Related]  

  • 37. Editorial: patients' preferences and health utility assessment in those with HCV treated with sofosbuvir - stating the obvious?
    Lim SG; Gandhi M; Chan E
    Aliment Pharmacol Ther; 2014 Nov; 40(9):1115. PubMed ID: 25280256
    [No Abstract]   [Full Text] [Related]  

  • 38. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
    Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
    Afdhal N; Zeuzem S; Kwo P; Chojkier M; Gitlin N; Puoti M; Romero-Gomez M; Zarski JP; Agarwal K; Buggisch P; Foster GR; Bräu N; Buti M; Jacobson IM; Subramanian GM; Ding X; Mo H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Mangia A; Marcellin P;
    N Engl J Med; 2014 May; 370(20):1889-98. PubMed ID: 24725239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PHOTON-2: hope for patients with HIV and HCV co-infection?
    Naggie S; Kim AY
    Lancet; 2015 Mar; 385(9973):1052-4. PubMed ID: 25659286
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.